Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.88 |
| ▸ | GLA | P06280 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211538 | 0.94 | CYP1A2 (0.78) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6209558 | 0.86 | CYP2C19 (0.81) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10448792 | 0.85 | CYP2C19 (0.69) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6236172 | 0.78 | HSD11B1 (1.00) | SMN1; SMN2HSD11B1GAALMNAALDH1A1 | |
| SCHEMBL3044364 | 0.78 | HSD11B1 (0.77) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27943800 | 0.77 | HSD11B1 (0.74) | SMN1; SMN2HSD11B1GAALMNAALDH1A1 | |
| SCHEMBL6212608 | 0.77 | HSD11B1 (0.74) | CYP2C19SMN1; SMN2HSD11B1GAALMNA | |
| SCHEMBL12184237 | 0.76 | CYP2C19 (0.70) | CYP2C9CYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL13873393 | 0.76 | CYP2C9 (0.76) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6344408 | 0.76 | HSD11B1 (0.72) | SMN1; SMN2HSD11B1GAALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | CYP2C9 482/4885CYP2C19 462/4885CYP1A2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.